Tweets
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Perspectives on TNFi: Dr. Jon Giles
Dr. Jon Giles offers his perspective and insight into data presented Saturday at #ACR21 annual meeting, specifically abstract #0457.
https://t.co/efIGP5HDUQ https://t.co/2oXkcLC028
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Psoriatic Arthritis: "What Matters" to Patients, Physicians
Dr. Swetha Ann Alexander ( @swethaann23 ) shares a summary of a poster from #ACR21 discussing what matters to patients and physicians when assessing psoriatic arthritis.
https://t.co/RPTmOeasUp https://t.co/K9oCpcvmKx
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
After failing a JAK inhibitor, can you still hit a JAK-pot?
Dr. Eric Dein ( @ericdeinmd) summarizes the abstracts presented at #ACR21.
https://t.co/qRM7daiBmh https://t.co/yM0pT091i9
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
#ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2021 Day 2.
https://t.co/Q6jCm29MN0 https://t.co/RTiifs5GxA
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Management of Pain in Spondyloarthritis: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0360 presented at the #ACR21 annual meeting.
https://t.co/C6QU1J6E18 https://t.co/EAfXarQ976
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Iberdomide for Lupus: Dr. Kathryn Dao ( @KDAO2011 ) discusses abstract #1458 presented at the #ACR21 annual meeting.
https://t.co/viLtTG0tzB https://t.co/rdWTXaquDS
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
JAKi For Refractory Still’s Disease: Dr. Olga Petryna ( @DrPetryna) discusses abstract #0195 presented at the #ACR21 annual meeting.
https://t.co/deSxncZOVP https://t.co/OJWGd4Osc4
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo)
🔹Prior-TNF vs TNF-naive: similar
Significant improvement:
🔹ACR 20/50/70 & HAQ-DI
🔹TJC/SJC/enthesitis
https://t.co/RV1zLpkUQe
#ACR21 Abst#1820 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Study presented by Dr. Michaela Koehm evaluated benefit of MTX in combination with ustekinmuab in PsA w/1° outcome of non-inferiority to placebo @ DAS28 @ wk 24.
🔹Randomized 173 pts
🔹52 weeks
🔹1° met
(continued below)
https://t.co/65ZXDjG9ur
#ACR21 Abst#L12 @RheumNow https://t.co/KsBbwJuLe8
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
Glucocorticoids (GC) in SLE on Belimumab
🔹Post-hoc, 5 phase 3 trials
🔹1° endpoint >25% pred↘️ to <7.5mg/d
🔹BEL n=1869; Placebo n=1217
🔹Baseline: 88% on GC; mean ~12.3mg/d pred
🔹Endpoint met by 17% BEL and 12% Pbo (p=0.0024)
https://t.co/xp9LamlpHZ
#ACR21 Abst#1283 @RheumNow
Pedro Castillo @_Castillo_Pedro ( View Tweet )
4 years 8 months ago
